Psoriasis News

Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.

Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis.

IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!

Three councilors join the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world.

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,525 cases.

Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color.

The Psoriasis: from Gene to Clinic International Congress provides a forum for psoriasis experts from around the world to present and discuss cutting-edge issues. You can download the full report or read a summary of some of the highlights.

IPC announces its official partnership with IFPA. Together we will work together to improve the lives of those living with psoriasis and psoriatic arthritis.

Three councilors join the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world.